Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: Potential targets for the development of new therapeutic agents

Progress in Neurobiology

Volumn 85, Issue 2, 2008, Pages 135-147

  Ward, Roberta J ^a,b   Lallemand, Frédéric ^a   de Witte, Philippe ^a   Dexter, David T ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Ethanol; Nicotine; Parkinson's disease; Therapeutic stratergies

Indexed keywords

1 (2 MERCAPTOETHYL)GUANIDINE; 1 (2 TRIFLUOROMETHYLPHENYL)IMIDAZOLE; 2 AMINO 5,6 DIHYDRO 6 METHYL 4H 1,3 THIAZINE; 2 HEPTYL N METHYLPROPARGYLAMINE; 2 IMINO 4 METHYLPIPERIDINE; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 7 NITROINDAZOLE; ALCOHOL; ALTINICLINE; ARGININE; DIPHENYLIODONIUM SALT; GUANIDINE DERIVATIVE; LADOSTIGIL; LAZABEMIDE; MONOAMINE OXIDASE INHIBITOR; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; N PROPYLARGININE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NEFIRACETAM; NICOTINE; PF 9601N; RASAGILINE; SAFINAMIDE; SELEGILINE; UNINDEXED DRUG; VARENICLINE;

ALCOHOL TOLERANCE; DOPAMINE RELEASE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; INFLAMMATION; MICROGLIA; NEUROCHEMISTRY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHOLINERGIC AGENTS; ETHANOL; HUMANS; PARKINSON DISEASE; RECEPTORS, NICOTINIC;

EID: 43249103338     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2008.03.003     Document Type: Review

References (124)

1. Alkondon M., Pereira E.F., and Albuquerque E.X. Mapping the location of functional nicotinic and gamma-aminobutyric acid A receptors on hippocampal neurons. J. Pharmacol. Exp. Ther. 279 (1996) 1491-1506
2. Am O.B., Amit T., and Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355 (2004) 169-172
3. Andre K., Schraub S., Mercier M., and Bontemps P. Role of alcohol and tobacco in the aetiology of head and neck cancer: a case-control study in the Doubs region of France. Oral. Oncol. Eur. J. Cancer 31B (1995) 301-309
4. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., and Ouirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58 (1992) 529-541
5. Badanich K.A., Maldonado A.M., and Kirstain C.L. Chronic ethanol exposure during adolescence increases basal dopamine in the nucleus accumbens septi during adulthood. Alcohol. Clin. Exp. Res. 31 (2007) 895-900
6. Belluardo N., Mudo G., Blum M., Amato G., et al. Neurotrophic effects of central nicotinic receptor activation. J. Neural Transm. Suppl. 60 (2000) 227-245
7. Bench C.J., Price G.W., Lammertsma A.A., Cremer J.C., Luthra S.K., et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur. J. Clin. Pharmacol. 40 (1991) 169-173
8. Benedetti M.D., Bower J.H., Maraganore D.M., McDonnell S.K., et al. Smoking, alcohol and coffee consumption preceding Parkinson's disease-a case control study. Neurology 14 (2000) 1350-1358
9. Benwell M., Balfour D., and Anderson J. Evidence that tobacco smoking increases the density of (-)[3H] nicotine binding sites in human brain. J. Neurochem. 50 (1988) 1243-1247
10. Berggren U., Fahlke C., and Balldin J. Transient increase in platelet monoamine oxidase B activity during early abstinence in alcoholics: implications for research. Alcohol Alcohol. 35 (2000) 377-2000
11. Bien T.H., and Burge R. Smoking and drinking: a review of the literature. Int. J. Addict. 25 (1990) 1429-1454
12. Bordia T., Grady S.R., McIntosh M., and Quik M. Nigrostriatal damage preferentially decreases a subpopulation of *α6β2 nAChRs in mouse, monkey and Parkinson's disease striatum. Mol. Pharmacol. 72 (2007) 52-61
13. Bowie A., and O'Neill L.A. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 59 (2000) 13-23
14. Breese C.R., Marks M.J., Logel J., Adams C.E., Sullivan B., Collins A.C., and Leonard S. Effect of smoking history on {3H] nicotine binding in human post-mortem brain. J. Pharmacol. Exp. Ther. 282 (1997) 7-13
15. Butt C.M., King N.M., Stitzel J.A., and Collins A.C. Interaction of the nicotinic cholinergic system with ethanol withdrawal. J. Pharmacol. Exp. Ther. 308 (2004) 591-599
16. Butt C.M., King N.M., Hutton S.R., Collins A.C., and Stitzel J.A. Modulation of nicotine but not ethanol preference by the mouse Chrna4 A529T polymorphism. Behav. Neurosci. 119 (2005) 26-37
17. Cardoso R.A., Brozowski S.J., Chavez-Noriega L.E., Harpold M., et al. Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 289 (1999) 774-780
18. Champtiaux N., Han Z.Y., Bessis A., Rossi F.M., Zoli M., Marubio L., McIntosh J.M., and Changeux J.P. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. 22 (2002) 1208-1217
19. Changeux J.P., and Edelstein S.J. Allosteric receptors after 30 years. Neuron 21 (1998) 959-980
20. Collins M.A., Ung-Chhun N., Cheng B.Y., and Pronger D. Brain and plasma tetrahydroisoquinolines in rats: effect of chronic ethanol intake and diet. J. Neurochem. 55 (1990) 1507-1514
21. Copeland R.L., Leggett Y.A., Kanaan Y.M., Taylor R.E., and Tizabi Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease. Neurotox. Res. 8 (2005) 289-293
22. Crichton R.R., and Ward R.J. Metal-based Neurodegeneration; From Molecular Mechanisms to Therapeutic Strategies (2006), J Wiley & Son pp. 1-227
23. Dahchour A., and De Wiite P. Effect of repeated ethnaol withdrawal on glutamate microdialysate in the hippocampus. Alcohol. Clin. Exp. Res. 23 (1999) 1698-1703
24. Davis R.L., and Synapin P.J. Interactions of alcohol and nitric oxide synthase in the brain. Brain Res. Rev. 49 (2005) 494-505
25. Demir B., Ucar G., Ulug B., Ulusoy S., Sevinc I., and Batur S. Platelet monoamine oxidase activity in alcoholism subtypes: relationship to personality traits and executive functions. Alcohol Alcohol. 37 (2002) 597-602
26. Ebbert J.O., Janney C.A., Sellers T.A., Folsom A.R., and Cerhan J.R. The association of alcohol consumption with coronary heart disease mortality and cancer incidence varies by smoking history. J. Gen. Intern. Med. 20 (2005) 14-20
27. Eensoo D., Paaver M., Pulver A., Harro M., and Harro J. Low platelet MAO activity associated with high dysfunctional impulsivity and antisocial behavior: evidence from drunk drivers. Psychopharmacology (Berl.) 172 (2004) 356-358
28. Eve D.J., Nisbet A.P., Kingsbury A.E., Hewson E.L., Daniel S.E., Lees A.J., Marsden C.D., and Foster O.J. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res. Mol. Brain Res. 63 (1998) 62-71
29. Farren C.K., Clare A.W., Tipton K.F., and Dinan T.G. Platelet MAO activity in subtypes of alcoholics and controls in a homogenous population. J. Psychiatr. Res. 32 (1998) 49-54
30. Fedele E., Varnier G., Ansaldo M.A., and Raiteri M. Nicotine administration stimulates in vivo N-methyl-d-aspartate receptor/nitric oxide/cyclicGMP pathway in rat hippocampus through glutamate release. Br. J. Pharmacol. 125 (1998) 1042-1048
31. Ferguson R.A., and Goldberg D.M. Genetic markers of alcohol abuse. Clin. Chim. Acta 257 (1997) 199-250
32. Formo L.S. Neuropathological features of Parkinson's, Huntington's and Alzheimer's diseases. Ann. NY Acad. Sci. 648 (1992) 6-16
33. Fowler J.S., Volkow N.D., Wang G.J., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 (1996) 733-736
34. Fowler J.S., Volkow N.D., Gene-Jack W., et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14065-14069
35. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vinol E.S., et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. 59 (2006) 174-177
36. Fuxe K., Aganti L.F., Jansson A., von Euler G., et al. The Biology of Nicotine Dependence. Ciba Foundation Symposium (1990), John Wiley & Sons Ltd., Great Britain pp. 113-126
37. Gatto E.M., Riobo N.A., Carreras M.C., Chernavsky A., Rubio A., Satz M.L., and Poderoso J.J. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 4 (2000) 534-539
38. Giovine A., Renis M., and Bertolino A. In vivo and in vitro studies on the effect of tetrahydropapaveroline and salsolinol on COMP and MAO activity in rat brain. Pharmacology 14 (1976) 86-94
39. Gorell J.M., Rybicki B.A., Johnson C.C., and Peterson E.L. Smoking and Parkinson's disease: a dose response relationship. Neurology 1 (1999) 115-119
40. Greeenberg S.S., Jie O., Zhao X., Wang J.F., and Giles T.D. The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol in vivo. Alcohol. Clin. Exp. Res. 22 (1998) 260S-265S
41. Grunblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111 (2004) 1543-1573
42. Guan Z.Z., Nordberg A., Mousavi M., Rinne J.O., et al. Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res. 956 (2002) 358-366
43. Hamada M., Higashi H., Nairn A.C., Greengard P., and Nishi A. Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J. Neurochem. 90 (2004) 1094-1103
44. Heap L., Ward R.J., Abiaka C., Dexter D., et al. The influence of acetaldehyde on oxidative status, dopamine metabolism and visual discrimination task. Biochem. Pharmacol. 50 (1995) 263-270
45. Heidbreder C., and De Witte P. Ethanol differentially affects extracellular monoamines and GABA in the nucleus accumbens. Pharmacol. Biochem. Behav. 46 (1993) 477-481
46. Hernan M.A., Chen H., Schwarzschild M.A., and Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann. Neurol. 54 (2003) 10-175
47. Herraiz T., and Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Bichem. Biophys. Res. Commun. 14 (2005) 378-386
48. Hunot S., Dugas N., Faucheux B., Hartmann A., et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
49. Janhunen S., and Ahtee L. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Neurosci. Biobehav. Rev. 31 (2007) 287-314
50. Jellinger K.A. Recent developments in the pathology of Parkinson's disease. J. Neural Transm. 1 Suppl. (2002) 347-376
51. Jimenez-Jimenez F.J., Mateo D., and Gimenez-Roldan S. Premorbid smoking, alcohol consumption and coffee drinking habits in Parkinson's disease: a case control study. Mov. Disord. 7 (1992) 339-344
52. Kaiser S., and Wonnacott S. Alpha-bungarotoxin-sensitive nicotine receptors indirectly modulate 3H-dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58 (2000) 312-318
53. Kashkin V.A., and De Witte P. Nicotine increases microdialysate brain amino acid concentrations and induces conditioned place preference. Eur. Neuropsychopharmacol. 15 (2005) 625-632
54. Khalil A.A., Davies B., and Castagnoli Jr. N. Isolation and characterisation of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg. Med. Chem. 14 (2006) 3392-3398
55. Kurosaki R., Muramatsu Y., Michimata M., Matsubara M., et al. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol. Res. 24 (2002) 655-662
56. Lallemand F., Ward R.J., and de Witte P. Modulation of cortical nitric oxide synthase after chronic alcoholisation: implication for hypervasculisation and behaviorial changes. Alcohol. Res. 9 (2004) 223-226
57. Lallemand F., Ward R.J., Dravolina O., and De Witte P. Nicotine-induced changes of glutamate and arginine in naive and chronically alcoholized rats: an in vivo microdialysis study. Brain Res. 1111 (2006) 48-60
58. Landau A.M., Kouassi E., Siegrist-Johnstone R., and Desbarats J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov. Disord. 22 (2007) 403-407
59. Lange K.W., Wells F.R., Jenner P., and Marsden C.D. Altered murscarinic and nicotinic receptor densties in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60 (1993) 197-203
60. Lena C., Changeux J.P., and Mulle C. Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J. Neurosci. 13 (1993) 2680-2688
61. ++ ions in nicotinic faciliatation of GABA release in mouse thalamus. J. Neurosci. 17 (1997) 576-585
62. Levecque C., Elbaz A., Clavel J., Richard F., et al. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS in a community-based case-control study. Hum. Mol. Genet. 12 (2003) 79-86
63. Levi F. Cancer prevention: epidemiology and perspectives. Eur. J. Cancer 35 (1999) 1912-1924
64. Linert W., and Jameson G.N.L. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J. Inorg. Biochem. 79 (2000) 319-326
65. Litchtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E., and Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology 21 (1982) 963-968
66. Liu Q., Zhang J., Zhu H., Qin C., Chen Q., and Zhao B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J. 21 (2007) 61-73
67. Maggio R., Riva M., Vaglini F., Fornai F., et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71 (1998) 2439-2446
68. Mansvelder H.D., and McGehee D.S. Lond-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27 (2000) 349-357
69. Marchi M., Risso F., Viola C., Cavazzani P., and Raiteri M. Direct evidence that release-stimulating alpha 7* nicotinic cholinergic receptors are localised on human and rat glutamatergic axon terminals. J. Neurochem. 80 (2002) 1071-1078
70. Masuda M., Kanai S., Miyasaka K., Funakoshi A., et al. Expression of interleukin-3 and tumor necrosis factor-beta mRNAs in cultured microglia. J. Neuroimmunol. 60 (1995) 83-91
71. Mazzio E.A., Kolta M.G., Reams R.R., and Soliman K.F.A. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective effects against oxidative neurotoxins in vitro. NeuroToxicology 26 (2005) 49-62
72. Mihailescu S., and Drucker-Colin R. Nicotine, brain nicotinic receptors and neuropsychiatric disorders. Arch. Med. Res. 31 (2000) 131-144
73. Newhouse P.A., Potter A., and Levin E.D. Nicotinic system involvement in Alzheimers and Parkinsons diseases. Implications for therapeutics. Drugs Aging 11 (1997) 206-228
74. Nguyen H.N., Rasmussen B.A., and Perry D.C. Subtype-selective upregulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J. Pharm. Exp. Ther. 307 (2003) 1090-1097
75. Niaura R., Jones C., and Kirkpatrick P. Varenicline. Nat. Rev. Drug Discov. 5 (2006) 537-538
76. Nomikos G.C., Schilstrom B., Hildebrand B.E., Panagis G., Grenhoff J., and Svensson T.H. Role of alpha 7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res. 113 (2000) 97-103
77. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., and Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 399-411
78. Ono K., Hirohata M., and Yamada M. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. Exp. Neurol. 205 (2007) 414-424
79. Oreland L. Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology 25 (2004) 79-89
80. Park H.J., Lee P.H., Ahn Y.W., Choi Y.J., et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci. 26 (2007) 79-89
81. Picciotto M.R., Zoli M., Rimondini R., Lena C., et al. Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine. Nature 8 (1998) 173-177
82. Pidoplichko V.I., Noguchi J., Areola O.O., Liang Y., Peterson J., Zhang T., and Dani J.A. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotinic addiction. Learn. Mem. 11 (2004) 60-69
83. Prendergast M.A., Harris B.R., Mayer S., and Littleton J.M. Chronic but not acute nicotine exposure attenuates ethanol withdrawal-induced hippocampal damage in vivo. Alcohol. Clin. Exp. Res. 24 (2000) 1583-1592
84. Quik M., Bordia T., and O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol. 74 (2007) 1224-1234
85. Ragonese P., Salemi G., Morgante L., Aridon P., Epifanio A., Buffa D., Scoppa F., and Savettiere G. A case-controlled study on cigarette, alcohol and coffee consumption preceding Parkinson's disease. Neuroepidemiology 22 (2003) 297-304
86. Rinne J.O., Myllykyla T., Lonnberg P., and Marjamaki P. A post-mortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 547 (1991) 167-170
87. Rothblat D.S., Rubin E., and Schneider J.S. Effects of chronic alcohol ingestion on the mesostriatal dopamine system in the rat. Neurosci. Lett. 300 (2001) 63-66
88. Salerno L., Sorrenti V., Di Giacomo C., Romeo G., and Soracusa M.A. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr. Pharm. Des. 8 (2002) 177-200
89. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., and Gray S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65 (2004) 1526-1535
90. Schapira M., Abagyan R., and Totrov M. Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMS Struct Biol. (2002) 2.1-2.8
91. Schreck R., Rieber P., and Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10 (1991) 2247-2258
92. Shapira A.H.V., Bezard E., Brotchie J., Calon F., et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. 5 (2006) 845-854
93. Sherman D.I.N., Ward R.J., and Peters T.J. The role of alcohol and aldehyde dehydrogenases in alcohol-related diseases. In: Weiner H., Holmes R.S., and Wermuth B. (Eds). Enzymology and Molecular Biology of Carbonyl Metabolism 4 (1994), Plenum, New York, USA 595-605
94. Shim I., Kim H.T., Kim Y.H., et al. Role of nitric oxide synthase inhibitors and NMDA receptor antagonsist in nicotine-induced behavioural sensitization in rats. Eur. J. Pharmacol. 17 (2002) 119-124
95. Shytle R.D., Moro T., Townsend K., Vendrame M., Sun N., Zeng J., Ehrhart J., Silver A.A., Sanberg P.R., and Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89 (2004) 337-343
96. Singh N., Pillay V., and Choomnara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 29-44
97. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., and Daly J.W. Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Equadoran poison frog. J. Am. Chem. Soc. 114 (1992) 3475-3478
98. Su Y., Han W.H., Li Y.D., and Block E.R. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am. J. Respir. 19 (1998) 19-825
99. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., et al. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharm. Exp. Ther. 283 (1997) 235-246
100. Teismann P., and Shulz J. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 318 (2004) 149-161
101. The Parkinson Study Group. Randomised placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 66 (2006) 408-410
102. Tonnessen B.H., Severson S.R., Hurt R.D., and Miller V.M. Modulation of nitric oxide synthase by nicotine. J. Pharmacol. Exp. Ther. 295 (2000) 601-606
103. Uzbay I.T., Celik T., Aydin A., Kayir H., et al. Effects of ethanol administration and ethanol withdrawal on cyclic guanosine 3′5′-monophosphate (cGMP) levels in the rat brain. Drug Alcohol Depend. 74 (2004) 55-59
104. Valles S.L., Blanco A.M., Pascual M., and Guerri C. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathol. 14 (2004) 365-371
105. Visanji N.P., O'Neill M.J., and Duty S. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51 (2006) 506-516
106. Wadia J.S., Chalmers-Redman R.M., Ju W.J., Carlile G.W., et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18 (1998) 932-947
107. Wang H., Liao H., Ochani M., Justiniani M., Lin X., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10 (2004) 1216-1221
108. Ward R.J., Abiaka C., and Peters T.J. Inflammation and tissue injury: the world of free radicals. J. Nephrol. 7 (1994) 89-96
109. Ward R.J., and Coutelle C. Women and alcohol susceptibility: could differences in alcohol metabolism predispose women to alcohol-related diseases. Arch Womens Ment. Health 6 (2003) 231-238
110. Ward R.J., Lallemand F., and De Witte P. Influence of chronic ethanol intoxication on the activities and functions of nitric oxide synthases in the brain. Alcohol Res. 9 (2004) 273-278
111. Ward R.J., and Peters T.J. Role of acetaldehyde in the pathogenesis of alcoholic liver disease. Mol. Aspects Med. 10 (1988) 179-190
112. Ward R.J., Zhang Y., Crichton R.R., Piette J., and De Witte P. Identification of the nuclear transcription factor NFkappaB in rat after in vivo ethanol administration. FEBS Lett. 389 (1996) 119-122
113. Watanabe H., Muramatsu Y., Kurosaki R., et al. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur. Neuropsychopharmacol. 14 (2004) 93-104
114. Weiner C., and Collins M. Tetrahydroisoquinoline derived from catecholamines or dopa; effects on brain tyrosine hydroxylase activity. Biochem. Pharmacol. 29 (1978) 411-417
115. Westerlund M., Belin A.C., Felder M.R., Olson L., and Galter D. High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson's disease. FEBS J. 274 (2007) 1212-1223
116. Wonnacott S., Irons J., Rapier C., Thorne B., and Lunt G.C. Presynaptic modulation of transmitter release by nicotinic receptors. Prog. Brain Res. 79 (1989) 157-163
117. Wonnacott S., Kaiser S., Mogg A., Soliakov L., and Jones I.W. Presynaptic nicotine receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 393 (2000) 51-58
118. Wonnacott S., Sidhpura N., and Balfour D.J. Nicotine: from molecular mechanisms to behaviour. Curr. Opin. Pharmacol. 5 (2005) 53-59
119. Youdim M.B.H., Edmondson D., and Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. 7 (2006) 295-309
120. Young W.F., Laws E.R., Sharbrough F.W., and Weinshilboum R.M. Human monoamine oxidase: lack of brain and platelet correlation. Arch. Gen. Psychiatry 43 (1986) 604-609
121. Zacny J.P. Behavioral aspects of alcohol-tobacco interactions. Recent Dev. Alcohol. 8 (1990) 205-219
122. Zhang Y., Crichton R.R., Jorens P.G., Ward R.J., et al. Decreased release of nitric oxide by alveolar macrophages after in vivo loading with iron or ethanol. Biochem. Pharmacol. 55 (1998) 21-25
123. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., and Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22 (2002) 8785-8789
124. Zuo Y., Kuryatov A., Lindstrom J.M., Yeh J.Z., and Narahashi T. Alcohol modulation of neuronal nicotinic acetylcholine receptors is alpha subumit dependent. Alcohol. Clin. Exp. Res. 26 (2002) 779-784